期刊文献+

非小细胞肺癌患者血清肿瘤异常蛋白的表达及其临床意义 被引量:8

Expression and significance of tumor abnormal protein in patients with non-small cell lung cancer
原文传递
导出
摘要 目的探讨肿瘤异常蛋白(TAP)在非小细胞肺癌(NSCLC)中的临床价值。方法202例肺部结节患者,根据术后病理分成NSCLC组(102例)和肺良性病变组(100例),测定患者外周血中TAP的表达。结果 NSCLC组TAP阳性表达率为73.53%,高于肺良性病变组的10.00%(P<0.01)。在NSCLC组中,腺癌和鳞状细胞癌的TAP阳性表达率分别为72.73%和78.57%。在肺良性病变组中,炎性结节、结核结节和不典型增生的TAP阳性表达率分别为4.62%、10.00%和33.33%。结论 NSCLC患者血清TAP表达量明显高于肺良性病变者,检测TAP表达有助于肺部病变性质的鉴别判断。 Objective To investigate the expression and significance of tumor abnormal protein(TAP)in the patients with non-small cell lung cancer(NSCLC).Methods According to postoperative pathological diagnosis,202 patients with pulmonary nodules were divided into two groups of A(with NSCLC,102cases)and B(with benign lung lesions,100cases).Serum levels of TAP expression were detected in two groups.Results The positive expression rate of TAP was higher in group A than that in group B(73.53% vs.10.00%)(P〈0.01).The expression rates of TAP in the patients with adenocarcinoma and squamous cell carcinoma in group A were 72.73% and 78.57%,which in the patients with inflammatory nodules,tuberculous nodules and atypical hyperplasia in group B were4.62%,10.00% and 33.33%,respectively.Conclusion Serum level of TAP expression in the patients with NSCLC is significantly higher than those with benign pulmonary lesions.Detection of serum TAP is helpful in the identification of benign and malignant pulmonary lesions.
出处 《江苏医药》 CAS 2017年第4期248-249,共2页 Jiangsu Medical Journal
基金 江苏省干部保健科研课题(BJ13012)
关键词 肿瘤异常蛋白 非小细胞肺癌 肺部结节 Tumor abnormal protein Non-small cell lung cancer Pulmonary nodules
  • 相关文献

参考文献2

二级参考文献13

  • 1Bray F, Parkin DM, Evaluation of data quality in the cancer registry: Principles and methods. Part I : Comparability, validity and timeliness [J]. Eur J Cancer, 2009, 45(5): 747-755. 被引量:1
  • 2Curado MP, Edwards B, Shin HR et al. Cancer incidence in five conti- nents, Vol. IX. IARC scientific publications No. 160[M]. Lyon: IARC, 2007. 被引量:1
  • 3Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IAtlC technical report No.19[M]. Lyon: IARC. 1994. 被引量:1
  • 4Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC technical report No.42[M]. Lyon: IARC, 2005. 被引量:1
  • 5Felay J. The IARCcrgTools program [CP/OL]. http://www.iaer.com.fr/iarc- crgtools.htm, 2006. 被引量:1
  • 6崔熙.TAP检测和癌症的早期防治[J].华东医药通讯,2003,14(4):5-7. 被引量:1
  • 7岑连乔 施南峰 史汉祥 等.TAP检测早期肿瘤的意义及来复宁对TAP阳性病例治疗效果观察[J].华东医药通讯,2003,14(5):18-20. 被引量:2
  • 8岑连乔.白介素—2治疗肿瘤异常蛋白阳性250例[J].华东医药通讯,2004,15(2):23-24. 被引量:1
  • 9全国肿瘤登记中心.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2004.48-50. 被引量:63
  • 10陈万青,张思维.中国肿瘤登记的代表性研究[J].中国肿瘤,2008,17(10):832-835. 被引量:12

共引文献346

同被引文献72

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部